{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,9]],"date-time":"2026-11-09T21:40:37Z","timestamp":1794260437681,"version":"4.9.0"},"reference-count":18,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2018,8,16]],"date-time":"2018-08-16T00:00:00Z","timestamp":1534377600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004440","name":"Wellcome Trust","doi-asserted-by":"publisher","award":["202834\/Z\/16\/Z"],"award-info":[{"award-number":["202834\/Z\/16\/Z"]}],"id":[{"id":"10.13039\/100004440","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000317","name":"Action Medical Research","doi-asserted-by":"publisher","award":["xxx"],"award-info":[{"award-number":["xxx"]}],"id":[{"id":"10.13039\/501100000317","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Orphanet J Rare Dis"],"published-print":{"date-parts":[[2018,12]]},"DOI":"10.1186\/s13023-018-0880-9","type":"journal-article","created":{"date-parts":[[2018,8,16]],"date-time":"2018-08-16T12:38:53Z","timestamp":1534423133000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":61,"title":["Annual severity increment score as a tool for stratifying patients with Niemann-Pick disease type C and for recruitment to clinical trials"],"prefix":"10.1186","volume":"13","author":[{"given":"Mario","family":"Cortina-Borja","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Danielle","family":"te Vruchte","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eugen","family":"Mengel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yasmin","family":"Amraoui","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jackie","family":"Imrie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simon A.","family":"Jones","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christine","family":"i Dali","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul","family":"Fineran","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Kirkegaard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Heiko","family":"Runz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robin","family":"Lachmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tatiana","family":"Bremova-Ertl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Strupp","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7614-0403","authenticated-orcid":false,"given":"Frances M.","family":"Platt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2018,8,16]]},"reference":[{"issue":"1","key":"880_CR1","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1007\/s40265-013-0164-6","volume":"74","author":"KA Lyseng-Williamson","year":"2014","unstructured":"Lyseng-Williamson KA. Miglustat: a review of its use in niemann-pick disease type C. Drugs. 2014;74(1):61\u201374.","journal-title":"Drugs"},{"key":"880_CR2","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1186\/1750-1172-7-76","volume":"7","author":"M Walterfang","year":"2012","unstructured":"Walterfang M, Chien YH, Imrie J, Rushton D, Schubiger D, Patterson MC. Dysphagia as a risk factor for mortality in Niemann-pick disease type C: systematic literature review and evidence from studies with miglustat. Orphanet J Rare Dis. 2012;7:76.","journal-title":"Orphanet J Rare Dis"},{"issue":"9","key":"880_CR3","doi-asserted-by":"publisher","first-page":"765","DOI":"10.1016\/S1474-4422(07)70194-1","volume":"6","author":"MC Patterson","year":"2007","unstructured":"Patterson MC, Vecchio D, Prady H, Abel L, Wraith JE. Miglustat for treatment of Niemann-pick C disease: a randomised controlled study. Lancet Neurol. 2007;6(9):765\u201372.","journal-title":"Lancet Neurol"},{"issue":"1","key":"880_CR4","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1038\/gim.2015.25","volume":"18","author":"CA Wassif","year":"2016","unstructured":"Wassif CA, Cross JL, Iben J, Sanchez-Pulido L, Cougnoux A, Platt FM, Ory DS, Ponting CP, Bailey-Wilson JE, Biesecker LG, Porter FD. High incidence of unrecognized visceral\/neurological late-onset Niemann-pick disease, type C1, predicted by analysis of massively parallel sequencing data sets. Genetics in medicine : official journal of the American College of Medical Genetics. 2016;18(1):41\u20138.","journal-title":"Genetics in medicine : official journal of the American College of Medical Genetics"},{"issue":"1","key":"880_CR5","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1002\/ajmg.b.30969","volume":"153B","author":"NM Yanjanin","year":"2010","unstructured":"Yanjanin NM, Velez JI, Gropman A, King K, Bianconi SE, Conley SK, Brewer CC, Solomon B, Pavan WJ, Arcos-Burgos M, Patterson MC, Porter FD. Linear clinical progression, independent of age of onset, in Niemann-Pick disease, type C. Am J Med Genet B Neuropsychiatr Genet. 2010;153B(1):132\u201340.","journal-title":"Am J Med Genet B Neuropsychiatr Genet"},{"key":"880_CR6","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1186\/1750-1172-8-35","volume":"8","author":"M Stampfer","year":"2013","unstructured":"Stampfer M, Theiss S, Amraoui Y, Jiang X, Keller S, Ory DS, Mengel E, Fischer C, Runz H. Niemann-pick disease type C clinical database: cognitive and coordination deficits are early disease indicators. Orphanet J Rare Dis. 2013;8:35.","journal-title":"Orphanet J Rare Dis"},{"issue":"355","key":"880_CR7","doi-asserted-by":"publisher","first-page":"355ra118","DOI":"10.1126\/scitranslmed.aad9823","volume":"8","author":"T Kirkegaard","year":"2016","unstructured":"Kirkegaard T, Gray J, Priestman DA, Wallom KL, Atkins J, Olsen OD, Klein A, Drndarski S, Petersen NH, Ingemann L, Smith DA, Morris L, Bornaes C, Jorgensen SH, Williams I, et al. Heat shock protein-based therapy as a potential candidate for treating the sphingolipidoses. Sci Transl Med. 2016;8(355):355ra118.","journal-title":"Sci Transl Med"},{"issue":"9","key":"880_CR8","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0006951","volume":"4","author":"CD Davidson","year":"2009","unstructured":"Davidson CD, Ali NF, Micsenyi MC, Stephney G, Renault S, Dobrenis K, Ory DS, Vanier MT, Walkley SU. Chronic cyclodextrin treatment of murine Niemann-pick C disease ameliorates neuronal cholesterol and glycosphingolipid storage and disease progression. PLoS One. 2009;4(9):e6951.","journal-title":"PLoS One"},{"issue":"14","key":"880_CR9","doi-asserted-by":"publisher","first-page":"5620","DOI":"10.1073\/pnas.1014890108","volume":"108","author":"NH Pipalia","year":"2011","unstructured":"Pipalia NH, Cosner CC, Huang A, Chatterjee A, Bourbon P, Farley N, Helquist P, Wiest O, Maxfield FR. Histone deacetylase inhibitor treatment dramatically reduces cholesterol accumulation in Niemann-Pick type C1 mutant human fibroblasts. Proc Natl Acad Sci U S A. 2011;108(14):5620\u20135.","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"3","key":"880_CR10","doi-asserted-by":"publisher","first-page":"1320","DOI":"10.1172\/JCI72835","volume":"124","author":"D te Vruchte","year":"2014","unstructured":"te Vruchte D, Speak AO, Wallom KL, Al Eisa N, Smith DA, Hendriksz CJ, Simmons L, Lachmann RH, Cousins A, Hartung R, Mengel E, Runz H, Beck M, Amraoui Y, Imrie J, et al. Relative acidic compartment volume as a lysosomal storage disorder-associated biomarker. J Clin Invest. 2014;124(3):1320\u20138.","journal-title":"J Clin Invest"},{"issue":"16","key":"880_CR11","doi-asserted-by":"publisher","first-page":"1368","DOI":"10.1212\/WNL.0000000000002041","volume":"85","author":"T Bremova","year":"2015","unstructured":"Bremova T, Malinova V, Amraoui Y, Mengel E, Reinke J, Kolnikova M, Strupp M. Acetyl-dl-leucine in Niemann-pick type C: a case series. Neurology. 2015;85(16):1368\u201375.","journal-title":"Neurology"},{"issue":"1","key":"880_CR12","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1002\/ajmg.b.30969","volume":"153B","author":"NM Yanjanin","year":"2010","unstructured":"Yanjanin NM, Velez JI, Gropman A, King K, Bianconi SE, Conley SK, Brewer CC, Solomon B, Pavan WJ, Arcos-Burgos M, Patterson MC, Porter FD. Linear clinical progression, independent of age of onset, in Niemann-pick disease, type C. Am J Med Genet B Neuropsychiatr Genet. 2010;153B(1):132\u201340.","journal-title":"Am J Med Genet B Neuropsychiatr Genet"},{"key":"880_CR13","doi-asserted-by":"publisher","DOI":"10.1007\/978-1-4899-3324-9","volume-title":"Density estimation","author":"BW Silverman","year":"1986","unstructured":"Silverman BW. Density estimation. London: Chapman and Hall; 1986."},{"key":"880_CR14","doi-asserted-by":"crossref","unstructured":"Friedman JH. A variable span scatterplot smoother. Laboratory for Computational Statistics, Stanford University Technical Report No 5 1984.","DOI":"10.21236\/ADA148241"},{"issue":"1\u20132","key":"880_CR15","doi-asserted-by":"publisher","first-page":"152","DOI":"10.1016\/j.ymgme.2009.06.008","volume":"98","author":"JE Wraith","year":"2009","unstructured":"Wraith JE, Baumgartner MR, Bembi B, Covanis A, Levade T, Mengel E, Pineda M, Sedel F, Topcu M, Vanier MT, Widner H, Wijburg FA, Patterson MC. Recommendations on the diagnosis and management of Niemann-pick disease type C. Mol Genet Metab. 2009;98(1\u20132):152\u201365.","journal-title":"Mol Genet Metab"},{"issue":"1","key":"880_CR16","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.jns.2006.05.054","volume":"249","author":"C Iturriaga","year":"2006","unstructured":"Iturriaga C, Pineda M, Fernandez-Valero EM, Vanier MT, Coll MJ. Niemann-pick C disease in Spain: clinical spectrum and development of a disability scale. J Neurol Sci. 2006;249(1):1\u20136.","journal-title":"J Neurol Sci"},{"issue":"2","key":"880_CR17","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1038\/nrd.2017.214","volume":"17","author":"FM Platt","year":"2018","unstructured":"Platt FM. Emptying the stores: lysosomal diseases and therapeutic strategies. Nat Rev Drug Discov. 2018;17(2):133\u201350.","journal-title":"Nat Rev Drug Discov"},{"issue":"21","key":"880_CR18","doi-asserted-by":"publisher","first-page":"1464","DOI":"10.1056\/NEJM199105233242104","volume":"324","author":"NW Barton","year":"1991","unstructured":"Barton NW, Brady RO, Dambrosia JM, Di Bisceglie AM, Doppelt SH, Hill SC, Mankin HJ, Murray GJ, Parker RI, Argoff CE, et al. Replacement therapy for inherited enzyme deficiency--macrophage-targeted glucocerebrosidase for Gaucher's disease. N Engl J Med. 1991;324(21):1464\u201370.","journal-title":"N Engl J Med"}],"container-title":["Orphanet Journal of Rare Diseases"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s13023-018-0880-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s13023-018-0880-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s13023-018-0880-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,7,9]],"date-time":"2024-07-09T08:23:45Z","timestamp":1720513425000},"score":1,"resource":{"primary":{"URL":"https:\/\/ojrd.biomedcentral.com\/articles\/10.1186\/s13023-018-0880-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,8,16]]},"references-count":18,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2018,12]]}},"alternative-id":["880"],"URL":"https:\/\/doi.org\/10.1186\/s13023-018-0880-9","relation":{},"ISSN":["1750-1172"],"issn-type":[{"value":"1750-1172","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,8,16]]},"assertion":[{"value":"5 July 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 July 2018","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 August 2018","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Standard protocol approvals, registrations and patient consents relate to this study.Research on data obtained from NPC patients were covered by REC\/IRB approvals 06\/MRE02\/85 (UK) and S-032\/2012 (Germany). Written informed consent, and if applicable, assent, were obtained in each centre.All study participants and\/or guardians of patients gave their informed consent to participation in the compassionate use of ADLL. This was a compassionate use observational study.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"FMP is a cofounder and consultant to IntraBio; and consultant to Actelion and Orphazyme. RL has received honoraria and travel support from Actelion and CTD Holdings. PF, MS and FP and DtV are shareholder in IntraBio. HR is a full-time employee at Biogen Inc. MS is Joint Chief Editor of the Journal of Neurology, Editor in Chief of Frontiers of Neuro-otology and Section Editor of F1000. He has received speaker\u2019s honoraria from Abbott, Actelion, Auris Medical, Biogen, Eisai, Gr\u00fcnenthal, GSK, Henning Pharma, Interacoustics, MSD, Otometrics, Pierre-Fabre, TEVA, UCB. He acts as a consultant for Abbott, Actelion, AurisMedical, Heel, IntraBio and Sensorion. TBE received travel grants and speaker\u2019s honoraria from Actelion and Sanofi-Genzyme. EM has received speaker\u2019s and consultation honoraria from Actelion, Biomarin, Orphazyme, Sanofi-Genzyme and Shire.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Publisher\u2019s Note"}}],"article-number":"143"}}